Comparison of HIV drug resistance profiles across HIV-1 subtypes A and D for patients receiving a tenofovir-based and zidovudine-based first line regimens in Uganda.
Abstract: As expected, discriminatory DRMs such as K65R, L74I, and Y115F were noted in Tenofovir (TDF) containing regimens while the Thymidine Analogue Mutations (TAMs) L210W and T215 mutations were in Zi
Result: K65R (95.2%, p = 0.00005), Y115F (85%, p = 0.005) and L74I (82.6%, p= 0.005) mutations appeared more in the TDF/3TC/EFV group as compared to AZT/3TC/EFV group.
Result: However, comparisons for individual mutations within the NRTI class of drugs indicated that mutations K65R, L74I, Y115F, L210W and T215 mutations differed significantly among the two regimens.
HIV-1 acquired drug resistance to integrase inhibitors in a cohort of antiretroviral therapy multi-experienced Mexican patients failing to raltegravir: a cross-sectional study.
Discussion: According to our findings, the frequency of the substitution Q148+ >=1 secondary mutation(s) (G140A/C/S, L74I or E138A/K/T) was 12%.
High resistance to reverse transcriptase inhibitors among persons infected with human immunodeficiency virus type 1 subtype circulating recombinant form 02_AG in Ghana and on antiretroviral therapy.
Discussion: Other mutations detected in this study, which have been shown to confer resistance to NRTIs, were M184I, T69N, L74I, M41L, K70R/E, T215Y/F, and K219E.
Discussion: The presence of the L74I mutation in combination with the M184 V causes high-level resistance to both Abacavir and Didanosine.
Human Immunodeficiency Virus-1 Viral Load Is Elevated in Individuals With Reverse-Transcriptase Mutation M184V/I During Virological Failure of First-Line Antiretroviral Therapy and Is Associated With Compensatory Mutation L74I.
PMID: 32105319
2020
The Journal of antimicrobial chemotherapy
Discussion: A limitation of this study was that our patient group were mainly ART-experienced and as such there may be a different prevalence of L74I in treatment-naive individuals.
Discussion: Furthermore, although L74I was associated with VF in two studies including the long-acting injectable cabotegravir, it is not known whether L74I contributed to VF or what the impact on dolutegravir might be.
Discussion: In most cases there was no change in variant frequencies, consistent with L74I being transmitted between individuals following a founder effect and L74I reverting rarely, even during second-line ART failure.
Discussion: In vitro studies are needed to determine whether L74I facilitates high-level
Variability in HIV-1 Integrase Gene and 3'-Polypurine Tract Sequences in Cameroon Clinical Isolates, and Implications for Integrase Inhibitors Efficacy.
PMID: 32106437
2020
International journal of molecular sciences
Result: Four other mutations were identified in cohort samples: M50I (in 6 samples), S119R (in 4 samples, all CRF02_AG), L74M (in 8 CRF02_AG and 1 CRF11_cpx samples), and L74I in 25 samples of which 22 (88%) were CRF02_AG (Table 2).
Result: Other mutations in database samples included M50I, L74M, L74I, S119R, S230N, and E138D, identified in 67 (31%), 9 (4%), 49 (22.8%), 1 (0.47%), 2 (0.93%), and 1 (0.47%) of database samples (Table 3), respectively.
Result: The INSTIs accessory RAMs identified in both AG and AG database samples included T97A, PMID: 32986709
2020
PloS one
Table: L74I
Genetic Features of HIV-1 Integrase Sub-Subtype A6 Predominant in Russia and Predicted Susceptibility to INSTIs.
Discussion: A lower genetic barrier for L74I mutations in sub-subtype A6 can lead to quicker development of drug resistance than subtype B, which is especially important in light of virological failures in patients with the L74I mutation from Russia in the ATLAS and FLAIR studies.
Discussion: Additionally, for position 74, we showed a lower genetic barrier for L74M and L74I mutations in sub-subtype A6.
Discussion: Five of them (R20K, I72V, L74I, S119P, and V201I) were described as INSTI resistant.
Discussion: Remarkably, the prevalence of 12 polymorphic mutations (K14R, PMID: 32843050
2020
Antimicrobial resistance and infection control
Conclusion: Another GRT, covering HIV-1 integrase (IN) region, performed on the sample plasma aliquot, revealed major RAMs, L74I, E138KQ, G140A, Q148R, and E157Q, to integrase strand transfer inhibitors (INSTI) including raltegravir, dolutegravir, bictegravir and elvitegravir.
Prevalence of acquired drug resistance mutations in antiretroviral- experiencing subjects from 2012 to 2017 in Hunan Province of central South China.
Prevalence of human immunodeficiency virus-1 drug-resistant mutations among adults on first- and second-line antiretroviral therapy in a resource-limited health facility in Busia County, Kenya.
PMID: 33654530
2020
The Pan African medical journal
HIV mutation literature information.
PMID: 
2020
AIDS research and therapy
Browser Board
Co-occurred Entities
Filtrator
ViMRT